1-Boc-L-吖啶-2-羧酸 | 51077-14-6

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-Boc-L-吖啶-2-羧酸
• 中文别名: 1-Boc-L-氮杂环丁烷-2-羧酸；(S)-N-BOC-氮杂环丁烷羧酸；(S)-1-叔丁氧羰基-氮杂环丁烷-2-甲酸；Boc-L-吖啶-2-羧酸；(S)-1-BOC-氮杂环丁烷-2-甲酸；(S)-N-BOC-氮杂环丁烷酸；(S)-N-BOC-吖啶-2-羧酸；(S)-N-叔丁氧羰基-吖啶-2-羧酸；1-BOC-L-环丁胺-2-羧酸；1-Boc-(S)-氮杂环丁烷-2-羧酸
• 英文名称: (S)-1-(t-butoxycarbonyl)azetidine-2-carboxylic acid
• 英文别名: (S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid；(2S)-1-tert-butoxycarbonylazetidine-2-carboxylic acid；(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-2-carboxylic acid
• CAS: 51077-14-6
• 化学式: C₉H₁₅NO₄
• mdl: MFCD01321011
• 分子量: 201.222
• InChiKey: JWJVSDZKYYXDDN-LURJTMIESA-N

物化性质

• 熔点：
  105-110 °C
• 沸点：
  339.14°C (rough estimate)
• 密度：
  1.2250 (rough estimate)
• 溶解度：
  二氯甲烷、DMSO、乙酸乙酯、甲醇
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 安全说明：
  S26,S36
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  存放在-15°C的阴凉干燥处。

SDS

Name:	(S)-N-BOC-Azetidine Carboxylic Acid 95% (98% E.E.) Material Safety Data Sheet
Synonym:	(S)-N-tert-Butoxycarbonyl-Azetidine-2-Carboxylic Acid
CAS:	51077-14-6

Section 1 - Chemical Product MSDS Name:(S)-N-BOC-Azetidine Carboxylic Acid 95% (98% E.E.) Material Safety Data Sheet
Synonym:(S)-N-tert-Butoxycarbonyl-Azetidine-2-Carboxylic Acid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51077-14-6	(S)-N-BOC-Azetidine Carboxylic Acid	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51077-14-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H15NO4
Molecular Weight: 201.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51077-14-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-N-BOC-Azetidine Carboxylic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 51077-14-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51077-14-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51077-14-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

S-氮杂环丁烷-2-羧酸是1-Boc-L-吖啶-2-羧酸的母核结构，作为一种重要的医药中间体，广泛存在于多种天然产物中。它不仅可用于合成凝血酶抑制剂Melagatran或Exenta，在多肽化学中还常作为脯氨酸的一种低级同系物。

用途

1-Boc-L-吖啶-2-羧酸是一种羧酸类有机化合物，主要用作医药中间体。

反应信息

• 作为反应物：
  描述：

  1-Boc-L-吖啶-2-羧酸 在 三乙胺 、 氯甲酸乙酯 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.41h， 生成 1-氮杂丁烷羧酸
  参考文献：
  名称：

  [EN] AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS D'AMIDE D'AZÉTIDINE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE

  摘要：

  本发明涉及式(I)的吡嗪酰胺衍生物衍生物，其中环A1、A2和A3如描述中所述，其药学上可接受的盐，其制备方法，含有一种或多种式(I)化合物的药物组合物，以及它们作为药物的用途，特别是它们作为促进睡眠的药物。

  公开号：

  WO2014141065A1
• 作为产物：
  描述：

  (S)-1-BOC-2-氮杂环丁烷甲醇 在 sodium hypochlorite 、 碳酸氢钠 、 硫酸 、 氟氯氰菊酯 、 sodium thiosulfate 、 sodium bromide 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 1-Boc-L-吖啶-2-羧酸
  参考文献：
  名称：

  Processes for producing azetidine-2-carboxylic acid and intermediates

  摘要：

  本发明的目的是提供一种生产氮杂环丙氨酸及其中间体的方法，该方法高效、经济且适合工业实践。本发明涉及一种生产氮杂环丙氨酸的方法，包括将一般式（1）所代表的4-氧代-2-氮杂环丙氨酸衍生物经氢化还原得到以下式（2）所示的氮杂环丙醇，将其与氨基保护剂处理得到以下一般式（3）所示的N-保护的氮杂环丙醇，将其与氧化剂处理得到以下一般式（4）所示的N-保护的氮杂环丙氨酸，并进一步对其氨基保护基进行消除。

  公开号：

  US06150535A1
• 作为试剂：
  描述：

  (S)-(-)-2-羧基环丁胺 、 水 、 三乙胺 、 2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 在 水 、 乙醚 、 ice 、 二氯甲烷 、 magnesium sulfate 、 正己烷 、 1-Boc-L-吖啶-2-羧酸 作用下， 以 1,4-二氧六环 、 正己烷 为溶剂， 反应 22.75h， 生成 1-Boc-L-吖啶-2-羧酸
  参考文献：
  名称：

  Compounds, compositions, and methods for controlling biofilms

  摘要：

  本发明提供一种氮杂环化合物、组合物和用于控制生物膜的方法，即破坏生物膜、预防生物膜形成、增强生物膜或改变生物膜。本发明还提供了筛选用于控制生物膜的测试化合物的方法和用于该方法的装置。

  公开号：

  US20060165648A1

文献信息

• Benzodiazepine and Pyridodiazepine Derivatives
  申请人：Bunnelle William H.

  公开号：US20110288069A1

  公开（公告）日：2011-11-24

  The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X 1 , Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

  本申请涉及式(I)的苯二氮卓和吡啶二氮卓衍生物，其中R1、R2、R3、R4、X1、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这类化合物的组合物，以及使用这类化合物和组合物治疗疾病症状的方法，以及识别这类化合物的方法。
• [EN] TETRAHYDRO-BENZODIAZEPINONES<br/>[FR] TÉTRAHYDRO-BENZODIAZÉPINONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015071393A1

  公开（公告）日：2015-05-21

  Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.

  本申请公开了具有I式化合物或其药用可接受盐的化合物，其中W、X、Y、Z、R1、R2、R3、R4和R5如本申请所述，并且使用所述化合物治疗癌症的方法。
• [EN] DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS<br/>[FR] DÉRIVÉS DE DIBENZOTHIOPHÈNE EN TANT QU'INHIBITEURS D'ADN-PK
  申请人：KUDOS PHARM LTD

  公开号：WO2010136778A1

  公开（公告）日：2010-12-02

  Compound formula I: wherein: X1 and X2 may be either (a) C and O, (b) N and N, or (c) C and NH, where the dotted bonds represents a double bond in the appropriate location; R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, or an optionally substituted C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; RN1 is selected from hydrogen and an optionally substituted C1-4 alkyl group; RC1 is selected from an optionally substituted C1-7 alkyl group, an optionally substituted C3-20 heterocyclyl group, or an optionally substituted C5-20 aryl group; or RN1 and RC1 may together form an optionally substituted C2-4 alkylene group.

  化合物公式I：其中：X1和X2可以是（a）C和O，（b）N和N，或（c）C和NH，其中点线代表适当位置的双键；R1和R2分别从氢，可选择的取代的C1-7烷基基团，可选择的取代的C3-20杂环基团，或可选择的取代的C5-20芳基基团中独立选择，或者可以与它们附着的氮原子一起形成具有4至8个环原子的可选择取代的杂环环；RN1从氢和可选择的取代的C1-4烷基基团中选择；RC1从可选择的取代的C1-7烷基基团，可选择的取代的C3-20杂环基团，或可选择的取代的C5-20芳基基团中选择；或RN1和RC1可以一起形成一个可选择取代的C2-4烷基烃基团。
• [EN] NAPHTHO[2,1 -D]THIAZOLE DERIVATIVES, COMPOSITIONS THEREOF AND METHODS OF TREATING DISORDERS<br/>[FR] DÉRIVÉS DE NAPHTO [2,1-D]THIAZOLE, COMPOSITIONS DE CEUX-CI ET MÉTHODES DE TRAITEMENT DE TROUBLES
  申请人：REVERIE LABS INC

  公开号：WO2021102410A1

  公开（公告）日：2021-05-27

  The present application relates to the compounds of formula (I) that inhibit CDK9, pharmaceutical compositions thereof and methods of making and using the same.

  本申请涉及抑制CDK9的化合物（I）的公式，以及其药物组合物的制备方法和使用方法。
• NOVEL AMINO PYRIMIDINE DERIVATIVES
  申请人：ANGST Daniela

  公开号：US20150152068A1

  公开（公告）日：2015-06-04

  The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

  本发明描述了新的氨基嘧啶衍生物及其药用盐，这些衍生物似乎与布鲁顿酪氨酸激酶（Btk）相互作用。因此，这些新型氨基嘧啶可能在治疗自身免疫性疾病、炎症性疾病、过敏性疾病、气道疾病（如哮喘和慢性阻塞性肺病（COPD））、移植排斥、血液起源或实体肿瘤等癌症方面具有有效性。